CA3227609A1 - Compositions and methods for prevention of retinal neurodegeneration - Google Patents

Compositions and methods for prevention of retinal neurodegeneration Download PDF

Info

Publication number
CA3227609A1
CA3227609A1 CA3227609A CA3227609A CA3227609A1 CA 3227609 A1 CA3227609 A1 CA 3227609A1 CA 3227609 A CA3227609 A CA 3227609A CA 3227609 A CA3227609 A CA 3227609A CA 3227609 A1 CA3227609 A1 CA 3227609A1
Authority
CA
Canada
Prior art keywords
apom
methods
mice
nucleic acid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227609A
Other languages
English (en)
French (fr)
Inventor
Rajendra APTE
Ali Javaheri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of CA3227609A1 publication Critical patent/CA3227609A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3227609A 2021-07-28 2022-07-26 Compositions and methods for prevention of retinal neurodegeneration Pending CA3227609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226756P 2021-07-28 2021-07-28
US63/226,756 2021-07-28
PCT/US2022/038278 WO2023009479A1 (en) 2021-07-28 2022-07-26 Compositions and methods for prevention of retinal neurodegeneration

Publications (1)

Publication Number Publication Date
CA3227609A1 true CA3227609A1 (en) 2023-02-02

Family

ID=85087191

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227609A Pending CA3227609A1 (en) 2021-07-28 2022-07-26 Compositions and methods for prevention of retinal neurodegeneration

Country Status (5)

Country Link
US (1) US20240350582A1 (https=)
EP (1) EP4376868A4 (https=)
JP (1) JP2024528893A (https=)
CA (1) CA3227609A1 (https=)
WO (1) WO2023009479A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592268B2 (en) * 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
EP3800191B1 (en) * 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
EP3668551A4 (en) * 2017-08-15 2021-04-14 Children's Medical Center Corporation APOM FC FUSION PROTEINS AND USES THEREOF
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用

Also Published As

Publication number Publication date
US20240350582A1 (en) 2024-10-24
JP2024528893A (ja) 2024-08-01
EP4376868A4 (en) 2025-05-14
WO2023009479A1 (en) 2023-02-02
EP4376868A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
Sengillo et al. Gene and cell‐based therapies for inherited retinal disorders: An update
Khalin et al. Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness
Ratican et al. Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and Leber’s hereditary optic neuropathy
Al-Saikhan The gene therapy revolution in ophthalmology
Jin et al. Multifunctional nanogel loaded with cerium oxide nanozyme and CX3CL1 protein: Targeted immunomodulation and retinal protection in uveitis rat model
Sundaresan et al. Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases
KR20190120197A (ko) 치료 및 신경보호 펩티드
Zarbin et al. Regenerative nanomedicine for vision restoration
Altay et al. Gene regulatory and gene editing tools and their applications for retinal diseases and neuroprotection: From proof-of-concept to clinical trial
Stieger et al. Gene therapy for vision loss—recent developments
Yao et al. Involvement of the NLRC4 inflammasome in promoting retinal ganglion cell death in an acute glaucoma mouse model
Kim Novel approaches for retinal drug and gene delivery
US20240350582A1 (en) Compositions and methods for prevention of retinal neurodegeneration
Murphy et al. Genetic engineering and the eye
US20230181563A1 (en) Akt3 modulators and methods of use thereof
US20220211624A1 (en) Fusion protein nanodisk compositions and methods of treatment
Chang Challenges of treatment methodologies and the future of gene therapy and stem cell therapy to treat retinitis pigmentosa
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
US11098296B2 (en) Mutants of cocaine esterase
US20240415930A1 (en) Compositions and methods for enhancing brain perfusion
TWI585205B (zh) ＭicroＲＮＡ－３２８反股組合物與其醫療用途
US20240050435A1 (en) Methods for treating cancer
CN110577942B (zh) 一种用于提高视网膜色素上皮细胞吞噬功能的活性肽及其应用
US12247196B2 (en) Engineered microorganisms and methods of making and using same
US20240424030A1 (en) Compositions, systems, and methods related to transgenic hookworms as a drug production and delivery technology

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240719

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250714

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250714